Noticias de ACON_US

Noticias del mercado

Últimas noticias sobre ACON_US — 238 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: ACON_US ✕ 238 resultados
05/05/2026 ACON_US — The Manila Times ES ← EN
Aclarion anuncia un segundo acuerdo comercial con Weill Cornell Medicine

Amplía el uso de Nociscan en un ensayo innovador con Roger Härtl, MD

05/05/2026 ACON_US — Yahoo Finance
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
05/05/2026 ACON_US — Investing.com UK
Aclarion establishes second trial agreement with Weill Cornell By Investing.com
05/05/2026 ACON_US — Investing.com
Aclarion establishes second trial agreement with Weill Cornell
05/05/2026 ACON_US — Investing.com India
Aclarion establishes second trial agreement with Weill Cornell
05/05/2026 ACON_US — Investing.com Canada
Aclarion establishes second trial agreement with Weill Cornell By Investing.com
05/05/2026 ACON_US — Stock Titan
Weill Cornell adds Aclarion scan to 2-year spine surgery trial
05/05/2026 ACON_US — MarketScreener
Aclarion announces second commercial agreement with Weill Cornell Medicine
01/05/2026 ACON_US — BizWest
Aclarion reports cash runway to ops into late 2027

Aclarion Inc. (Nasdaq: ACON), una tecnología de atención médica con sede en Broomfield que a principios de este año recaudó 10,4 millones de dólares a través de una venta de acciones, informó recientemente que sus "recursos en efectivo existentes son suficientes para financiar operaciones hasta la segunda mitad de 2027".

30/04/2026 ACON_US — Investing.com Australia
Aclarion reports 196% jump in Nociscan scan volumes in Q1 By Investing.com
30/04/2026 ACON_US — Investing.com UK
Aclarion reports 196% jump in Nociscan scan volumes in Q1 By Investing.com
30/04/2026 ACON_US — MarketScreener ES ← EN
Aclarion ofrece sólidos resultados en el primer trimestre de 2026 con un crecimiento anual del 196 % en el volumen de escaneo, lo que refleja una adopción clínica acelerada

Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption

30/04/2026 ACON_US — The Globe and Mail ES ← EN
Aclarion ofrece sólidos resultados en el primer trimestre de 2026 con un crecimiento anual del 196 % en el volumen de escaneo, lo que refleja una adopción clínica acelerada

Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption

30/04/2026 ACON_US — Stock Titan
Back-pain scan use rose 196% as Aclarion funds operations into 2027
30/04/2026 ACON_US — Yahoo Finance
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
30/04/2026 ACON_US — Investing.com
Aclarion reports 196% jump in Nociscan scan volumes in Q1 By Investing.com
30/04/2026 ACON_US — Investing.com
Aclarion reports 196% jump in Nociscan scan volumes in Q1
30/04/2026 ACON_US — MEXC
Aclarion Reports 196% Annual Scan Volume Growth in Q1 2026, Fueled by Accelerating Clinical Adoption of Nociscan
30/04/2026 ACON_US — The Manila Times
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
29/04/2026 ACON_US — Medical Buyer
Aclarion names Daniel Keefe as commercial director for Western US

Página 7 de 12

keyboard_arrow_up